| 2026-08-18 | 8-K | Form 8-K, Item 1.01 |
| 2026-08-10 | Press release | BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, at 8:00AM |
| 2026-08-06 | Deck | Second Quarter 2026 Financial Results |
| 2026-08-06 | Press release | BioMarin Reports Second Quarter 2026 Financial and Operating Results |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| Transcript | Q2 FY26 earnings call transcript |
| 2026-08-05 | Press release | BioMarin Reports Second Quarter 2026 Financial and Operating Results |
| 2026-07-30 | Press release | BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30p |
| 2026-07-27 | Press release | BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Ne |
| 2026-07-13 | Press release | U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vo |
| 2026-07-13 | 8-K | Form 8-K/A, Item 8.01 |
| 2026-06-16 | Press release | BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 |
| 2026-06-04 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-20 | Press release | BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia |
| 2026-05-18 | Press release | BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency |
| 2026-05-05 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-04 | Press release | BioMarin Reports First Quarter 2026 Financial and Operating Results |
| 2026-05-04 | Deck | Presentation of Q1 2026 |
| 2026-05-04 | Press release | Press Release of Q1 2026 |
| 2026-05-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-02 | Press release | BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and |
| 2026-04-27 | Press release | BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET |
| 2026-04-27 | Press release | BioMarin Completes Acquisition of Amicus Therapeutics |
| 2026-04-27 | 8-K | Form 8-K, Item 1.01 |
| 2026-04-23 | 8-K | Form 8-K, Item 8.01 |
| 2026-04-21 | Press release | BioMarin Announces Board Leadership Transition |
| 2026-04-21 | Proxy | Definitive proxy statement |
| Transcript | Q1 FY26 earnings call transcript |
| 2026-03-16 | 8-K | Form 8-K, Item 8.01 |
| 2026-03-12 | Press release | BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and A |
| 2026-02-27 | Press release | U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Ol |
| 2026-02-26 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-24 | Press release | BioMarin to Participate in Four Upcoming Investor Conferences in March |
| 2026-02-24 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-23 | Deck | Earnings presentation · Q4 2025 · Feb 2026 |
| 2026-02-23 | Press release | Press release · Q4 2025 · Feb 2026 |
| 2026-02-23 | Press release | Press release · Q4 2025 · Feb 2026 |
| 2026-02-23 | Press release | BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results |
| 2026-02-23 | 8-K | Form 8-K, Item 2.02 results |